Last edition
News about "Chiesi Global Rare Diseases"
EU Approves Chiesi's LOJUXTA for Pediatric HoFH Patients
The European Commission has approved Chiesi’s LOJUXTA (lomitapide) for children aged 5 years and older with Homozygous Familial Hypercholesterolaemia (HoFH), expanding treatment options for this ultra-rare genetic disorder.
Chiesi Global Rare Diseases | 25/06/2026 | By News Bureau
Chiesi Presents New Metreleptin Data and Patient Care Insights at ENDO 2026
Chiesi Global Rare Diseases presented five new studies at ENDO 2026, highlighting advances in metreleptin therapy for lipodystrophy, potential combination treatments, and the urgent need to address mental health challenges and care gaps among patients with the rare disorder.
Chiesi Global Rare Diseases | 20/06/2026 | By News Bureau
Chiesi Global Rare Diseases Announces EC Approval of Lojuxta Capsules
Chiesi Global Rare Diseases has secured European Commission approval for Lojuxta (lomitapide) in children aged 5 years and older with Homozygous Familial Hypercholesterolaemia (HoFH), expanding treatment options for this ultra-rare genetic cholesterol disorder across the EU.
Chiesi Global Rare Diseases | 08/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy